The effects of concurrent atorvastatin therapy on the pharmacokinetics of intravenous midazolam

Anaesthesia

Volumn 58, Issue 9, 2003, Pages 899-904

  Mc Donnell, Conor G ^a   Harte, S ^a   O'Driscoll, J ^a   O'Loughlin, C ^a   Van Pelt, F ^b   Shorten, G D ^a  

^a University College Cork and INFANT Centre   (Ireland)

^b UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

Cytochrome P450; Drug interactions; midazolam, atorvastatin

Indexed keywords

ATORVASTATIN; CYTOCHROME P450; MIDAZOLAM; MORPHINE SULFATE; THIOPENTAL; VECURONIUM;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; ELECTIVE SURGERY; ENDOTRACHEAL INTUBATION; FEMALE; GASTROINTESTINAL SYMPTOM; GENERAL ANESTHESIA; HEPATITIS; HUMAN; LONG TERM CARE; MALE; MUSCLE DISEASE; MYOPATHY;

AGED; ANESTHESIA, GENERAL; ANESTHETICS, INTRAVENOUS; ANTICHOLESTEREMIC AGENTS; DRUG INTERACTIONS; FEMALE; HALF-LIFE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MATCHED-PAIR ANALYSIS; MIDAZOLAM; MIDDLE AGED; PYRROLES;

EID: 0041324754     PISSN: 00032409     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2044.2003.03339.x     Document Type: Article

References (25)

1. Stein EA. Managing dyslipidemia in the high-risk patient. American Journal of Cardiology 2002; 89: 50C-57C.
2. Lousberg TR, Denham AM, Rasmussen JR. A comparison of clinical outcome studies among cholesterol-lowering agents. Annals of Pharmacotherapy 2001; 35: 1599-607.
3. Aronow WS. Cholesterol 2001. Rationale for lipid-lowering in older patients with or without CAD. Geriatrics 2001; 56 (22-5): 28-30.
4. Feely J, McGettigan P, Kelly A. Growth in use of statins after trials is not targeted to most appropriate patients. Clinical Pharmacology and Therapeutics 2000; 67: 438-41.
5. Lennernas H, Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clinical Pharmacokinetics 1997; 32: 403-25.
6. Wrighton SA, Stevens JC. The human hepatic cytochromes P450 involved in drug metabolism. Critical Reviews in Toxicology 1992; 22: 1-21.
7. Dain JG, Fu E, Gorski J, Nicolletti J, Scallen TJ. Biotransformation of fluvastatin sodium in humans. Drug Metabolism and Disposition 1993; 21: 567-72.
8. Boberg M, Angerbauer R, Fey P, et al. Metabolism of cerivastatin by human liver microsomes in vitro. Characterization of primary metabolic pathways and of cytochrome P450 isozymes involved. Drug Metabolism and Disposition 1997; 25: 321-31.
9. Wang RW, Kari PH, Lu AYH, et al. Biotransformation of lovastatin. IV. Identification of cytochrome P450 1991, 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes. Archives in Biochemistry & Biophysics 1991; 290: 355-61.
10. Prueksaritanont T, Gorham LM, Ma B, et al. In vitro metabolism of simvastatin in humans [SBT] identification of metabolising enzymes and effect of the drug on hepatic P450s. Drug Metabolism and Disposition 1997; 25: 1191-9.
11. Ishigama M, Honda T, Takasaki W, et al. A comparison of the effects of 3-hydroxy-3-methylglutaryl-co-enzyme A (HMG CoA) reductase inhibitors on the CYP 3A4-dependent oxidation of mexazolam in vitro. Drug Metabolism and Disposition 2001; 29: 282-8.
12. Gorski JC, Hall SD, Jones DR, VandenBranden M, Wrighton SA. Regioselective biotransformation of midazolam by members of the human cytochrome P450 1994, 3A (CYP3A) subfamily. Biochemical Pharmacology 1994; 47: 1643-53.
13. Tateishi T, Krivoruk Y, Ueng YF, Wood AJ, Guengerich FP, Wood M. Identification of human liver cytochrome P-450 3A4 as the enzyme responsible for fentanyl and sufentanil N-dealkylation. Anesthesia and Analgesia 1996; 82: 167-72.
14. Fabre G, Rahmani R, Placidi M et al. Characterisation of midazolam metabolism using human hepatic microsomal fractions and hepatocytes in suspension obtained by perfusing whole human livers. Biochemical Pharmacology 1988; 37: 4389-97.
15. Tsunoda SM, Velez RL, Von Moltke LL, Greenblatt DJ. Differentiation of intestinal and hepatic cytochrome P450 1999, 3A activity with use of midazolam as an in vivo probe: Effect of ketoconazole. Clinical Pharmacology & Therapeutics 1999; 66: 461-71.
16. Lenert, Peck Brown and Perlin. http://perso.clubinternet.fr/alaffont/compute/ibw/peck/peck.htm.
17. Greenblatt DJ, Shader RI, Franke K, et al. Pharmacokinetics and bioavailability of intravenous, intramuscular and oral lorazepam in humans. Journal of Pharmaceutical Science 1979; 68: 57-63.
18. Boxenbaum HG, Riegelman S, Elashoff RM. Statistical estimations in pharmacokinetics. Journal of Pharmacokinetics and Biopharmacy 1974; 2: 123-48.
19. Olkkola KT, Ahonen J, Neuvonen PJ. The effects of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesthesia and Analgesia 1996; 82: 511-16.
20. Smith MT, Heazlewood V, Eadie MJ, Brophy TO, Tyrer JH. Pharmacokinetics of midazolam in the aged. European Journal of Clinical Pharmacology 1984; 26: 381-8.
21. Smith MT, Eadie MJ, Brophy TO. The pharmacokinetics of midazolam in man. European Journal of Clinical Pharmacology 1981; 19: 271-8.
22. Bornemann LD, Min BH, Crews T et al. Dose dependent pharmacokinetics of midazolam. European Journal of Clinical Pharmacology 1985; 29: 91-5.
23. Kantola T, Kivisto KT, Neuvonen PJ. Effect of itraconazole on the pharmacokinetics of atorvastatin. Clinical Pharmacology and Therapeutics 1998; 64: 58-65.
24. Norman DJ, Illingworth DR, Munson J, Hosenpud J. Myolysis and acute renal failure in a heart-transplant patient receiving lovastatin. New England Journal of Medicine 1988; 318: 46-7.
25. Kim RB. Drugs as P-glycoprotein substrates, inhibitors, and inducers. Drug Metabolism in Review 2002; 34: 47-54.